4.7 Article

Interrater reliability and aspects of validity of the myositis damage index

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 70, Issue 7, Pages 1272-1276

Publisher

B M J PUBLISHING GROUP
DOI: 10.1136/ard.2010.142117

Keywords

-

Categories

Funding

  1. Ministry of Education, Youth and Sports [MSM 0021620812]
  2. Swedish Rheumatism Association
  3. MRC [G0601943] Funding Source: UKRI
  4. Medical Research Council [G0601943] Funding Source: researchfish
  5. Versus Arthritis [18474] Funding Source: researchfish

Ask authors/readers for more resources

Objective To test the interrater reliability, internal consistency and aspects of validity of the myositis damage index (MDI) in the assessment of damage in adult patients with idiopathic inflammatory myopathy (IIM). Methods 95 patients were assessed in six centres as part of this cross-sectional international study. Two parts of a MDI were used to assess disease damage, the MDI and the myositis damage score (MYODAM). The myositis disease activity assessment tool (MDAAT) was used to assess disease activity. Interrater reliability was assessed using intraclass correlation coefficient (ICC). Spearman's rank correlation coefficient was used to measure the convergent validity of cross-sectional scores between the two parts of the damage tool and to determine the correlation between the respective components of the damage and activity tools. Results In general, the damage index appears to have good interrater reliability for most of the systems with an ICC greater than 0.65. Convergent validity between the two parts of the damage tool showed good correlation for the individual organ systems (r>0.8). There were weak correlations between some parts of the MDI and corresponding components of the MDAAT. Conclusion The MDI is a comprehensive tool to assess damage in patients with myositis. With physician education and emphasis to record items that have been diagnosed since the myositis diagnosis, the MDI will provide a valuable tool to assess damage in future clinical trials and longitudinal studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available